For research use only. Not for therapeutic Use.
Less active (ca 100-fold) enantiomer of SLV 319 (Axon 1713) that is a potent and selective CB1 receptor antagonist
| Catalog Number | I011527 |
| CAS Number | 656827-86-0 |
| Molecular Formula | C23H20Cl2N4O2S |
| Purity | ≥95% |
| IUPAC Name | (4R)-5-(4-chlorophenyl)-N-(4-chlorophenyl)sulfonyl-N'-methyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide |
| InChI | InChI=1S/C23H20Cl2N4O2S/c1-26-23(28-32(30,31)20-13-11-19(25)12-14-20)29-15-21(16-5-3-2-4-6-16)22(27-29)17-7-9-18(24)10-8-17/h2-14,21H,15H2,1H3,(H,26,28)/t21-/m0/s1 |
| SMILES | CN=C(NS(=O)(=O)C1=CC=C(C=C1)Cl)N2C[C@H](C(=N2)C3=CC=C(C=C3)Cl)C4=CC=CC=C4 |
| Reference | JH Lange etal. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists. J. Med.l Chem. 2004, 47(3), 627–643.
JH Lange and CG Kruse. Recent advances in CB1 cannabinoid receptor antagonists. Curr. Opin. Drug Discov. Devel. 2004, 7(4), 498-506.
AB Need et al. The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats. Psychopharmacol. 2006, 184(1), 26–35. |
